FinDogFinDog
Friday, October 30, 2026Closing data · 4:00 PM ET
English
Log in

VEEV

Veeva SystemsNYSE · Health Care Technology · Health Care
Previous close
312.96
Change
+2.62 / +0.84%
FinDog View
Neutral
52-Week Range ?
148.05 – 325.99
P/E (TTM) ?
50.4
Forward P/E ?
33.6
Based on consensus earnings for the next 12 months
Market Cap
$52.3B
1M
+9.64%
S&P 500 −0.91% over same period
Volume / Avg Volume
1.4M / 1.5M
0.94× average
Latest earnings analysisFY2027 Q2Reported 2026-08-26

Veeva FY27 Q2: $928.0M revenue, 18% growth, but a near-flat guide

Veeva beat its own guidance and raised the full-year view, yet the quarter's real message is the outlook: next-quarter revenue of $932–935 million sits just 0.6% above the $927.96 million it just reported. That is why the call here is Neutral rather than Bullish. Read the beat first, then the guidance, then check whether the cash flow was earned or merely collected.

Read the full analysis →
Revenue$0.93BYoY +17.60%
EPS (non-GAAP)$2.35
Next-quarter revenue guidance$0.93B ±0.16%Below estimatesest. $0.95B
Next-day move+15.20%

Price History

Closing price · USD1M6M1Y5Y
150200250300350EEEEEE2021-102023-012024-042025-082026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 50.81M6M1Y5Y
42.54547.55052.5552026-092026-102026-102026-102026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2026-11-18
in 16 days · After hours
Consensus EPS
$2.39
Last quarter EPS $2.35
Avg. next-day move over the last 6 reports
±9.2%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 30 of its 5-year rangeCheap
5-year range 30.8 – 65.4 · Median 55.5
Last 4 quarters: $473M in buybacks + $0 in dividends, 0.90% of market cap combined
P/E (TTM)
50.4
P/B
6.9
P/S
14.8
PEG
2.09
Earnings Reaction
Over the last 6 reports, the stock moved ±9.2% on average on the first trading day after, rising 3 times
Most recent +15.20%
Guidance Credibility
Of the last 4 next-quarter revenue guides, 4 were met; actual results averaged 2.8% above guidance
Volatility & Correlation
1-year beta 0.55 · Correlation with S&P 500 0.16Low beta
Annualized volatility 43% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 6 · $15.2MNet selling $15.2M
  • 10-14Faddis JonathanSVP, Gen. Counsel, SecretarySell$1.6M5,198 shares · 3 trades · Avg price 299.72
  • 10-02Rizzo Daniel JEVP, Sales, Consulting, & SvcsSell$1.3M4,841 shares · 2 trades · Avg price 276.51
  • 09-14Schwenger Thomas D.Pres. & Chief Customer OfficerSell$0.27M1,000 shares · Avg price 265.20
  • 09-09Hung PriscillaDirectorSell$0.20M750 shares · Avg price 261.04
  • 08-27Schwenger Thomas D.Pres. & Chief Customer OfficerSell$2.8M10,000 shares · Avg price 281.33
  • 08-13Schwenger Thomas D.Pres. & Chief Customer OfficerSell$9.0M36,000 shares · 3 trades · Avg price 250.23
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2027 Q20.93+17.6%75.0%0.280.270.241.66
FY2027 Q10.88+16.3%75.0%0.270.261.131.57
FY2026 Q40.84+16.0%74.5%0.250.240.111.48
FY2026 Q30.81+16.0%75.4%0.240.240.191.40
FY2026 Q20.79+16.7%75.3%0.200.200.241.19
FY2026 Q10.76+16.7%77.1%0.230.230.881.37
FY2025 Q40.72+14.3%74.9%0.190.200.071.17
FY2025 Q30.70+13.4%75.1%0.180.190.161.13
FY2025 Q20.68+14.6%74.8%0.170.170.091.04
FY2025 Q10.65+23.6%73.3%0.160.160.760.98
FY2024 Q40.63+11.9%72.4%0.140.150.060.90
FY2024 Q30.62+11.6%72.8%0.130.140.080.83

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView